

RUTH ARNON

LIST OF PUBLICATIONS

A. Original Papers

1. Studies on the toxic action of thallium on the intact rat.
R. Erez-Arnon and H. Meyer. *Bull. Res. Council Israel*. 5A, 98 (1955).
2. The synthesis of n-carboxyanhydrides of some trifunctional amino acids without the use of protecting groups.
A. Berger, J. Kurtz, T. Sadeh, A. Yaron, R. Arnon and Y. Lapidoth. *Bull. Res. Council Israel*. 7A, 98 (1958).
3. Studies on the chemical basis of antigenicity of proteins.
1. Antigenicity of poly-peptidyl gelatins.
M. Sela and R. Arnon. *Biochem. J.* 75, 91 (1960).
4. Studies on the chemical basis of antigenicity of proteins.
2. Antigenicity specificity of polytyrosyl gelatins.
R. Arnon and M. Sela. *Biochem. J.* 75, 103 (1960).
5. Studies on the chemical basis of antigenicity of proteins.
3. The role of rigidity in the antigenicity of polypeptidyl gelatins.
M. Sela and R. Arnon. *Biochem J.* 77, 394 (1960).
6. Poly-L-cyclohexylalanine and poly-L-cyclohexylalanyl proteins.
M. Sela and R. Arnon. *J. Am. Chem. Soc.* 82, 2625 (1960).
7. A specific synthetic polypeptide antigen.
M. Sela and R. Arnon. *Biochim. Biophys. Acta.* 40, 382 (1960).
8. Isolation of antibodies to gelatin from antigen-antibody complex by proteolysis.
R. Arnon and M. Sela. *Science.* 132, 86 (1960).
9. Studies on the chemical basis of the antigenicity of proteins.
Synthesis, characterization and immunogeneity of some multichain and linear polypeptides containing tyrosine.
M. Sela, S. Fuchs and R. Arnon. *Biochem. J.* 85 223 (1962).
10. The amino acid composition of chromatographically purified pepsinogen.
R. Arnon and G.E. Perlmann. *J. Biol. Chem.* 238, (1963).
11. Relation of immunological and enzymic properties to structural modifications pepsinogen.
R. Arnon and G.E. Perlmann. *J. Biol. Chem.* 238, 963 (1963).
12. Antibodies to pepsinogen and pepsinogen modifications.

- R. Arnon and G.E. Perlmann. *Ann. N.Y. Acad. Sci.* **103**, 744 (1963).
13. Synthesis of poly-L-lysine and poly-L-lysyl albumin via Σ ,N-trifluoroacetyl- α -N-carboxy-L-lysine anhydride.
M. Sela, R. Arnon and I. Jacobson. *Biopolymers* **1**, 517 (1963).
 14. Polylysine-specific antibodies and their reaction with oligolysines.
R. Arnon, M. Sela, A. Yaron and H.A. Sober. *Biochemistry* **4**, 948 (1965).
 15. Immunospecific and nonspecific fixation of complement by poly-L-lysine.
R. Arnon, H. Levinhar and M. Sela. *J. Med. Sci.* **1**, 404 (1965).
 16. The reaction of papain with antipapain.
R. Arnon. *Immunochemistry.* **2**, 107 (1965).
 17. Cystine and other amino acids in fingernails of cystinuric patients.
W. Pruzanski and R. Arnon. *Lancet* **II**, p. 60 1965.
 18. Determination of cystine and other amino acids in the fingernails of Members of various ethnic groups in Israel.
W. Pruzanski and R. Arnon. *Israel J. Med. Sci.* **2**, 465 (1966).
 19. Immunological studies on specific antibodies against trypsin.
R. Arnon and B. Schechter. *Immunochemistry.* **3**, 451 (1966).
 20. Isolation and characterization of active fragments obtained by cleavage of immunoglobulin G with cyanogen bromide.
H.J. Cahnmann, R. Arnon and M. Sela. *J. Biol. Chem.* **241**, 3247 (1966).
 21. The immune response of inbred strains of guinea pigs to polylysyl rabbit serum albumin.
S. Ben-Efraim, R. Arnon and M. Sela. *Immunochemistry.* **3**, 491 (1966).
 22. Reaction of enzymes with N-carboxy- α -amino acid anhydrides.
M. Sela and R. Arnon. In "*Methods in Enzymology*", C.H.W. Hirs. ed., Vol. XI, p. 580, Academic Press, 1967.
 23. Biological activity of the cleavage product of human immunoglobulin G with cyanogen bromide.
M. Lahav, R. Arnon and M. Sela, *J. Exp. Med.* **125**, 787 (1967).
 24. Antibodies to papain - resolution on DEAE-Sephadex into fractions with different precipitating capacities.
E. Shapira and R. Arnon. *Biochim. Biophys. Acta.* **140**, 177 (1967).
 25. Cytolipin H-specific antibodies obtained with a synthetic polypeptide conjugate.
R. Arnon, M. Sela, E.S. Rachaman and D. Shapiro. *Eur. J. Biochem.* **2**, 80 (1967).
 26. Antibodies to papain - A selective fractionation according to inhibitory capacity.

- R. Arnon and E. Shapira. *Biochemistry*. **6**, 3942 (1967).
27. The mechanism of inhibition of papain by its specific antibodies.
E. Shapira and R. Arnon. *Biochemistry*. **6**, 3951 (1967).
28. The chemical basis of antigenicity (published in Hebrew).
M. Sela and R. Arnon, "*Harefuah*" **73**, 93 (1967).
29. Preparation et propriétés de derives poly-DL-alanyles d'un
inhibiteur de la trypsin (inhibiteur de Kunitz and Northrop).
R. Acher, J. Chauvet, R. Arnon and M. Sela. *Eur. J. Biochem.* **3**, 476, (1968).

30. Effect of immunization course on inhibitory capacity of anti-enzyme antibodies.
E. Shapira and R. Arnon. *Immunochemistry*. **5**, 501 (1968).
31. Cleavage of horse immunoglobulin by cyanogen bromide.
M.L. Ernst, R. Arnon and M. Sela. *Immunochemistry* **5**, 513, (1968).
32. A selective fractionation of anti-lysozyme antibodies of different determinant specificities.
R. Arnon. *Eur. J. Biochem.* **5**, 583 (1968).
33. Comparison between antigenic structure of mutually related enzymes. A study with papain and chymopapain.
R. Arnon and E. Shapira. *Biochemistry* . **7**, 4196 (1968).
34. Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate.
R. Arnon and M. Sela. *Proc. Natl. Acad. Sci.* **62**, 163 (1969).
35. Cleavage of one specific disulfide bond in papain.
E. Shapira and R. Arnon. *J. Biol. Chem.* **244**, 1026 (1969).
36. Crystalline papain derivative containing an intramolecular mercury bridge.
R. Arnon and E. Shapira. *J. Biol. Chem.* **244**, 1033 (1969).
37. Substrate effect on enzyme-antienzyme reaction.
H.S. Novey, E. Shapira and R. Arnon. *Israel J. Med. Sci.* **5**, 270 (1969).
38. Antibodies to a phyto-oestrogen: Antigenicity of genistein coupled to a synthetic polypeptide.
S. Bauminger, H.R. Lindner, E. Perel and R. Arnon. *J. Endocrinology*. **44**, 567 (1969).
39. An immunological approach to the study of evolution of trypsins.
R. Arnon and H. Neurath. *Proc. Natl. Acad. Sci.* **64**, 1323 (1969).
40. Immunological studies on trypsin and trypsinogen derivatives.
R. Arnon and H. Neurath. *Immunochemistry*. **7**, 241 (1970).
41. Immunological cross-reactivity as a guide to structural homology in trypsin and chymotrypsin.
M. Sanders, K. Walsh and R. Arnon. *Biochemistry* **9**, 2356 (1970).
42. Lack of immunological cross-reaction between bovine α -lactalbumin and hen's egg white lysozyme.
R. Arnon and E. Maron. *J. Mol. Biol.* **51**, 703 (1970).
43. Basic encephalitogenic protein: A simplified purification on sulfoethyl Sephadex.
H. Hirshfeld, D. Teitelbaum, R. Arnon and M. Sela. *FEBS Lett.* **7**, 317 (1970).

44. Sphingomyelin-specific antibodies elicited by synthetic conjugates.
D. Teitelbaum, R. Arnon, M. Sela, Y. Rabinsohn and D. Shapiro.
Israel J. Med. Sci. **6**, 442 (1970).

45. Immunological comparison of bird and human lysozymes and their "loop" regions.
E. Maron, R. Arnon, M. Sela, J.-P. Perin and P. Jolles. *Biochim. Biophys. Acta.* **214**, 222 (1970).
46. Chemical and immunological characterization of a unique antigenic region in lysozyme.
E. Maron, C. Shiozawa, R. Arnon and M. Sela. *Biochemistry.* **10**, 763, (1971).
47. Specific immunoassay for quantitative determination of human trypsin in intestinal content.
E. Shapira, R. Arnon and R. Russell. *J. Lab. Clin. Med.* **77**, 877 (1971).
48. Strain dependent differences in the specificity of antibody response toward lysozyme.
E. Mozes, E. Maron, R. Arnon and M. Sela. *J. Immunol.* **106**, 862 (1971).
49. Specific excitation energy transfer from antibodies to dansyl-labeled antigen. Studies with the "loop" peptide of hen egg-white lysozyme.
I. Pecht, E. Maron, R. Arnon and M. Sela. *Eur. J. Biochem.* **19**, 368 (1971).
50. Sequential appearance of antibodies directed against different antigenic determinants of hen egg-white lysozyme.
E. Maron, R. Arnon and B. Bonavida. *Eur. J. Immunol.* **2**, 181 (1971).
51. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.
D. Teitelbaum, A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela. *Eur. J. Immunol.* **1**, 242: **197** (1971).
52. Antibodies reactive with a native lysozyme elicited by a completely synthetic antigen.
R. Arnon, E. Maron, M. Sela and C.B. Anfinsen. *Proc. Natl. Acad. Sci.* **68**, 1450 (1971).
53. An immunological approach to the structural relationship between hen egg-white lysozyme and bovine α -lactalbumin.
R. Arnon and E. Maron. *J. Mol. Biol.* **60**, 225 (1971).
54. Reaction of enzymes with N-carboxy α -amino acid anhydrides.
M. Sela and R. Arnon. In "*Methods in Enzymology*", G.H.W. Hirs and S. Timaseff, eds., Academic Press, N.Y. p. 553 (1972).
55. Cell-mediated vs. humoral response in the cross reaction between hen egg-white lysozyme and bovine α -lactalbumin.
E. Maron, C. Webb, D. Teitelbaum and R. Arnon. *Eur. J. Immunol.* **2**, 294, (1972).
56. Synthetic vaccines - Dream or reality?
R. Arnon, in *Immunity of Viral and Rickettsial Diseases*, A. Kohen and A.M. Klinberg, eds., Plenum Press, N.Y., p. **209** (1972).

57. Protection against experimental allergic encephalomyelitis by Treatment with the basic protein of brain followed by a basic synthetic polypeptide.
D. Teitelbaum, C. Webb, A. Meshorer, R. Arnon and M. Sela. *Nature*. **40**, 564-566 (1972).
58. Suppression by several synthetic polypeptides of experimental Allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.
D. Teitelbaum, C. Webb, A. Meshorer, R. Arnon and M. Sela. *Eur. J. Immunol.* **3**, 273 (1973).
59. In-vivo and in-vitro immunological cross-reaction between basic Encephalitogen and synthetic basic polypeptide capable of suppressing experimental allergic encephalomyelitis.
C. Webb, D. Teitelbaum, R. Arnon and M. Sela. *Eur. J. Immunol.* **3**, 279 (1973).
60. The role of specific amino acid residues in the antigenic reactivity of the loop
E. Teicher, E. Maron and R. Arnon. *Immunochemistry*. **10**, 265 (1973).
61. Correlation between strain dependent differences in susceptibility to experimental allergic encephalomyelitis and the immune response to encephalitogenic protein in inbred guinea pigs.
C. Webb, D. Teitelbaum, R. Arnon and M. Sela. *Immunol. Commun.* **2**, 185, (1973).
61. Genetic control of immune response toward the loop region of lysozyme.
E. Maron, H.I. Scher, E. Mozes, R. Arnon and M. Sela. *J. Immunol.* **111**, 101 (1973).
62. Structural and functional comparison of antibodies to common and Specific determinants on papain and chymopapain.
J. Eder and R. Arnon. *Immunochemistry*. **10**, 535 (1973).
64. Sphingomyelin-specific antibodies elicited by synthetic conjugates.
D. Teitelbaum, R. Arnon and M. Sela. *Immunochemistry*. **10**, 735 (1973).
65. Preparation of antisera to α -fetoprotein making use of estradiol affinity Chromatography.
R. Arnon, E. Teicher, M. Bustin and M. Sela. *FEBS Lett.* **32**, 335, (1973).
66. Cellular studies of the genetic control of immune response towards the loop region of lysozyme.
E. Mozes, G.M. Shearer, E. Maron, R. Arnon and M. Sela. *J. Immunol.* **111**, 1429 (1973).
67. Immunoreactive properties of the plasma HGH from patients with the syndrome of familial dwarfism and high plasma IR-HGH.
R. Eshet, Z. Laron, M. Brown and R. Arnon. *J. Clin. Endocrinol. Metab.* **37**, 819 (1973).

68. Immunological behavior of HGH from plasma of patients with familial dwarfism and high IR-HGH in radioimmunoassay system using the cross-reaction between HGH and HCS.
R. Eshet, Z. Laron, M. Brown and R. Arnon. *Hormone and Metabolic Res.* **6**, 79: (1974).
69. Structural aspects of lysozyme - from the viewpoint of an antibody.
R. Arnon. In "*Lysozyme*", N.Y., Academic Press, p. 105 (1974).
70. Correlation of structural differences in several bird lysozymes and their loop region with immunological cross-reactivity.
M. Fainaru, A.C. Wilson and R. Arnon. *J. Mol. Biol.* **84**, 635 (1974).
71. Molecular basis of the antigenic difference between two closely Related lysozymes of known sequence: Effect of internal substitutions.
E.M. Prager, M. Fainaru, A.C. Wilson and R. Arnon. *Immunochemistry.* **11**, 153 (1974).
72. Immunoglobulins in the airway, washings and bile secretions of chickens.
D. Katz, A. Kohn and R. Arnon. *Eur. J. Immunol.* **4**, 494 (1974).
73. Suppression of experimental allergic encephalomyelitis in rhesus monkey by a synthetic basic copolymer.
D. Teitelbaum, C. Webb, M. Bree, A. Meshorer, R. Arnon and M. Sela. *J. Clin. Immunol. Immunopathol.* **3**, 256 (1974).
74. Immunogenicity and antigenic specificity of the loop fragment of lysozyme.
B. Geiger and R. Arnon. *Eur. J. Immunol.* **4**, 632 (1974).
75. Conformational-dependent antigenic determinants in proteins and synthetic polypeptides.
R. Arnon. In "*Peptides, Polypeptides and Proteins*", N. Lotan, M. Goodman and E.R. Blout, eds., Wiley, p. 538 (1974).
76. Lymphocytes sensitized to basic encephalitogen in multiple sclerosis patients unresponsive to steroid therapy.
C. Webb, D. Teitelbaum, O. Abramsky, R. Arnon and M. Sela, *The Lancet II.* 66, (1974).
77. Purification of human hexosaminidases A and B by affinity chromatography.
B. Geiger, Y. Ben-Yoseph and R. Arnon. *FEBS Lett.* **45**, 276 (1974).
78. Antibody-mediated thermal stabilization of human hexosaminidases.
Y. Ben-Yoseph, B. Geiger and R. Arnon. *Immunochemistry.* **12**, 221 (1974).
79. Correlation of conformation and biological activity in lysozyme "loop" homologs.
R. Arnon, E. Teicher and H.A. Scheraga. *J. Mol. Biol.* **90**, 403

(1974).

80. Conformation and physico-chemical factors influencing antigenicity.
R. Arnon. *Progr. Immunol.* II, Vol. 2, p. 5, L. Brent and J. Holbrow.
eds. North Holland, 1974.
81. Lipid-specific antibodies elicited with synthetic lipid conjugates.
R. Arnon and D. Teitelbaum. *Chem. Phys. Lipids* . **13**, 352 (1974).
82. Enzyme inhibition by antibodies.
R. Arnon. The Seventh Karolinska Symposium on Research
Methods in Reproductive Endocrinology. *Acta Endocr.*
(KBH). Suppl. 194, **78**, 133 (1975).
83. Neuritogenic and encephalitogenic properties of the peripheral nerve basic
proteins.
O. Abramsky, D. Teitelbaum, C. Webb and R. Arnon.
J. Neuropathol. Exp. Neurol. **34**, 36 (1975).

84. Fractionation of functional lymphocytes sensitized to basic Encephalitogen on derivatized collagen and gelatin gels.
C. Webb, D. Teitelbaum, H. Rauch, **A. Maoz, R. Arnon and S. Fuchs.** *J. Immunol.* **114**, 1469 (1975).
85. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities.
E. Hurwitz, R. Levy, R. Maron, M. Wilchek, R. Arnon and M. Sela. *Cancer Res.* **35**, 1175 (1975).
86. The specific cytotoxic effects of daunomycin conjugates to anti-tumor antibodies.
R. Levy, E. Hurwitz, R. Maron, R. Arnon and M. Sela. *Cancer Res.* **35**, 1182 (1975).
87. Cell-mediated immunity to neural antigens in idiopathic polyneuritis and myeloradiculitis.
O. Abramsky, C. Webb, D. Teitelbaum and R. Arnon. *Neurology.* **25**, 1154 (1975).
88. Cellular immune response to peripheral nerve basic protein in idiopathic facial paralysis (Bell's Palsy).
O. Abramsky, C. Webb, D. Teitelbaum and R. Arnon. *J. Neurol. Sci.* **26**, 13 (1975).
89. Specific determination of N-acetyl- β -D-hexosaminidase isozymes A and B by radioimmunoassay and radial immunodiffusion.
B. Geiger, R. **Navon**, Y. Ben-Yoseph and R. Arnon. *Eur. J. Biochem.* **56**, 311 (1975).
90. Inverse relationship between net electric charge on the antigen and that on the sensitized cell in cellular immune response - demonstration with basic encephalitogen of the brain.
D. Teitelbaum, C. Webb, H. Rauch, Y. Karniely, R. Arnon and M. Sela. *J. Exp. Med.* **142**, 701 (1975).
91. Immunological relationships among hexosaminidases of different species. B. Geiger, Y. Ben-Yoseph and R. Arnon. *Immunochemistry.* **13**, 485 (1976).
92. Immunological cross-reactivity of antibodies to a synthetic undecapeptide of carcinoembryonic antigen with the intact protein and human sera.
R. Arnon, M. Bustin, E. Calef, S. Chaitchick, J. Haimovich, N. Novik and M. Sela. *Proc. Natl. Acad. Sci.* **73**, p. 2123-2127 (1976).
93. Hexosaminidase A in amniotic fluid of Tay-Sachs fetuses.
B. Geiger, R. Navon and R. Arnon. *Clin. Chem.* **24**, p. 1131-1133 (1978).
94. Fab dimers of anti-tumor immunoglobulins as covalent carriers of daunomycin.
E. Hurwitz, R. Maron, R. Arnon and M. Sela. *Cancer Biochemistry Biophysics.* **2**, 197-202 (1976).
95. Immunological studies on tyrosinase induction in neurospora.

- T. Katan, R. Arnon and E. Galun. *Eur. J. Biochem.* **59**, 387 (1975).
96. Changes in the GABA system in EAE-induced paralysis.
Z. Gottesfeld, D. Teitelbaum, C. Webb and R. Arnon.
J. Neurochemistry. **27**, 695-699 (1976).

97. Stabilization of human β -D-N-acetylhexosaminidase A towards proteolytic inactivation by coupling it to poly-N-vinylpyrrolidone.
B. Geiger, B.U. v. Specht and R. Arnon. *Eur. J. Biochem.* **73**, 141 (1977).
98. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.
C. Webb, D. Teitelbaum, A. Herz, R. Arnon and M. Sela.
Immunochemistry **13**, 333 (1976).
99. Chemical characterization and subunit structure of human N-acetyl hexosaminidases A and B.
B. Geiger and R. Arnon. *Biochemistry.* **15**, 3484 (1976).
100. Site directed tumor chemotherapy.
R. Arnon. McGraw-Hill Yearbook of Science & Technology. (1977).
101. Experimental allergic neuritis induced by a basic neuritogenic protein (P₁L) of human peripheral nerve origin.
O. Abramsky, D. Teitelbaum and R. Arnon. *Eur. J. Immunol.* **7**, 213 (1977).
102. Strain differences in susceptibility to experimental allergic encephalo-myelitis and the immune response to the encephalitogenic determinant in inbred guinea pigs.
D. Teitelbaum, C. Webb, R. Arnon and M. Sela. *Cell. Immunol.* **29**, 265 (1977).
103. Conformational changes and complement activation induced upon antigen binding to antibodies.
I. Pecht, B. Ehrnberg, E. Calef and R. Arnon. *Biochem. Biophys. Res. Commun.* **74**, 302 (1977).
104. Antiviral effect on MS-2 coliphage obtained with a synthetic antigen.
H. Langbeheim, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci.* **73**, 4636 (1976).
105. Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalitis.
O. Abramsky, D. Teitelbaum and R. Arnon. *J. Neurol. Sci.* **31**, 433 (1977).
106. Regulation of autosensitization to encephalitogenic myelin basic protein by macrophage-associated and soluble antigen.
L. Steinman, I.R. Cohen, D. Teitelbaum and R. Arnon. *Nature.* **265**, 173 (1977).
107. Inactivation of neurogenic 5-hydroxytryptamine receptors in guinea pigs with experimental allergic encephalomyelitis (EAE) induced paralysis.
M. Weinstock, S. Shoham-Moshonov, D. Teitelbaum and R. Arnon.
Brain Res. **125**, 192 (1977).
108. Viroimmunoassay utilizing a synthetic peptide: A test equivalent to the carcinoembryonic antigen radioimmunoassay.
R. Arnon, N. Novik, J. Haimovich and S. Chaitchik. *Isr. J. Med. Sci.* **13**, 1022: (1977).
109. Specific cytotoxicity of drugs chemically linked to antibody.

R. Levy, E. Hurwitz, R. Maron, R. Arnon and M. Sela. *Transplant. Proc.Suppl.* **1**, 485: (1975).

110. Immunochemical and biochemical investigation of hexosaminidase
B. Geiger, R. Arnon and K. Sandhoff. *Amer. J. Human Genetics.*
29, 508 (1977).
111. Higher anti-tumor efficacy of daunomycin when linked to dextran.
in-vitro and in-vivo studies.
A. Bernstein, E. Hurwitz, R. Maron, R. Arnon, M. Sela and M.
Wilchek. *J. Natl. Cancer Inst.* **60, 379** (1978).
112. Daunomycin-immunoglobulin conjugates, uptake and activity in-vitro.
E. Hurwitz, R. Maron, R. Arnon, M. Wilchek and M. Sela.
Eur. J. Cancer. **14, 1213** (1978).
113. The use of antibodies to tumor cells as carriers of chemotherapeutic
drugs. The effect in-vivo in two murine experimental tumor systems.
E. Hurwitz, R. Maron, E. Bernstein, M. Wilchek, M. Sela and R.
Arnon, *Intl. J. Cancer* **21, 747** (1978).
114. Adjuvant effect of a peptidoglycan attached covalently to a
synthetic antigen provoking anti-phage antibodies.
H. Langbeheim, R. Arnon and M. Sela. *Immunology* **35, 573** (1978).
115. Biochemical and immunochemical characterization of hexosaminidase P.
B. Geiger, E. Calef and R. Arnon. *Biochemistry* **17, 1713** (1978).
116. Purification, biochemical and immunological characterization of
hexosaminidase A from variant AB of infantile GM₂ gangliosidosis.
K. Sandhoff, B. Konzelman, B. Geiger and R. Arnon. *Eur. J. Biochem.* **84, 27** (1978)
117. Cellular immune response toward MS-2 phage and a synthetic
fragment of its coat protein.
H. Langbeheim, D. Teitelbaum and R. Arnon. *Cell. Immunol.* **38, 193** (1978).
118. Immunochemical analysis of the conformational properties of intermediates
trapped in the folding and unfolding of bovine pancreatic trypsin inhibitor.
T.E. Creighton, E. Kalef and R. Arnon. *J. Mol. Biol.* **123, 129** (1978).
119. Genetic control of susceptibility to experimental allergic encephalomyelitis
D. Teitelbaum, Z. Lando and R. Arnon. In "*Genetic Control of
Autoimmune Diseases*", N. Rose, ed., Elsevier, p. 365 (1978).
120. Enzyme replacement trial in Tay-Sachs disease.
B.U. von Specht, B. Geiger, R. Arnon, J. Passwell, G. Keren, B.
Goldman and B. Padeh. *Neurology.* **29, 848** (1979).
121. Diotype anti-idiotypic complexes in cerebrospinal fluids of multiple
sclerosis patients.
R. Arnon, R. Kelley, V.N. Schumaker and J. Fahey. *J. Neurol. Sci.* **43, 149** (1979).
122. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing
EAE in guinea pigs.

- A.B. Keith, R. Arnon, D. Teitelbaum, A. Caspary and H.M. Wisniewski. *J. Neurol. Sci.* **42**, 267 (1979).
123. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.
Z. Lando, D. Teitelbaum and R. Arnon. *J. Immunol.* **123**, 2156 (1979).
 124. Genetic control of susceptibility to experimental allergic encephalomyelitis in mice.
Z. Lando, D. Teitelbaum and R. Arnon. *Immunogenetics.* **9**, 435 (1979).
 125. Binding of anti-tumor immunoglobulins and their daunomycin conjugates to the tumor and its metastases. In-vitro and in-vivo studies with Lewis lung carcinoma.
A. Hurwitz, B. Schechter, R. Arnon and M. Sela. *Intl. J. Cancer.* **24**, 461 (1979).
 126. Anti-ganglioside antibodies in sera of multiple sclerosis patients.
R. Arnon, E. Crisp, R. Kelley, G.W. Ellison, L.W. Meyers and W.W. Tourtellote. *J. Neurol. Sci.* **46**, 179-186 (1980).
 127. The effect of single amino acid substitution on the antigenic specificity of the loop region of lysozyme.
I. Ibrahimi, J. Eder, E.M. Prager, A.C. Wilson and R. Arnon. *Mol. Immunol.* **17**, 37-46 (1980).
 128. Anti-viral antibodies - combined use of synthetic antigens and synthetic adjuvants.
M. Sela, E. Mozes and R. Arnon. *J. Inf. Diseases,* **44**, (1980).
 129. Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice.
Z. Lando, D. Teitelbaum and R. Arnon. *Nature.* **287**, 551-552 (1980).
 130. Anti-viral response elicited by a completely synthetic antigen with built-in adjuvanticity.
R. Arnon, M. Sela, M. Parant and L. Chedid. *Proc. Natl. Acad. Sci.* **77**, 6769-6773 (1980).
 131. Dynamics of antibody- and lectin-mediated endocytosis of hapten-containing liposomes by murine macrophages.
B. Geiger, C. Gitler, E. Calef and R. Arnon. *Eur. J. Immunol.* **11**, 710-716 (1981).
 132. Unresponsiveness to experimental allergic encephalomyelitis in mice: Replacement of suppressor cells by a soluble factor.
Z. Lando, Y. Dori, D. Teitelbaum and R. Arnon. *J. Immunol.* **127**, 1915-1919 (1981).
 133. Genetic analysis of susceptibility to experimental allergic encephalomyelitis in guinea pigs.
D. Teitelbaum and R. Arnon. *J. Immunogenetics.* **8**, 107-112 (1981).
 134. The immunological response in mice unresponsive to experimental allergic encephalomyelitis.
Z. Lando, D. Teitelbaum and R. Arnon. *J. Immunol.* **126**, 1526-1528 (1981).

135. Reduced toxicity of daunomycin by conjugation to dextran.
F. Levi-Schaffer, A. Bernstein, A. Meshorer and R. Arnon. *Cancer Treatment Reports*. **66**, 107-114 (1982).
136. Lack of H-2 restriction of suppressor factor specific to myelin basic protein.
Lando, Y. Dori, D. Teitelbaum and R. Arnon. *J. Neurol. Sci.* **53**, 113-123 (1982).
137. Multiple sclerosis: Trial of a synthetic polypeptide.
M.B. Bornstein, A.L. Miller, D. Teitelbaum, R. Arnon and M. Sela.
Ann. Neurol. **11**, 317-319 (1982).

138. In-vitro and in-vivo efficacy of conjugates of daunomycin with anti-tumor antibodies.
R. Arnon and M. Sela. *Immunol. Rev.* **62**, 5-27: (1982).
139. Successful immunization with a totally synthetic diphtheria vaccine.
Audibert, M. Jolivet, L. Chedid, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci.* **79**, 5042-5046 (1982).
140. Protection against *Schistosoma mansoni* achieved by immunization with sonicated parasite.
R. Horowitz, M. Smolarsky and R. Arnon. *Eur. J. Immunol.* **12**, 327-332 (1982).
141. Anti-influenza response achieved by immunization with a synthetic antigen.
G.M. Muller, M. Shapira and R. Arnon. *Proc. Natl. Acad. Sci. USA.* **79**, 569-573 (1982).
142. Targeted chemotherapy: Drugs conjugated to anti-tumor antibodies.
R. Arnon and M. Sela. *Cancer Surveys.* **1**, 429-449 (1983).
143. Report of a preliminary trial of the effectiveness of a synthetic polypeptide Copolymer 1) for the treatment of multiple sclerosis.
M.B. Bornstein, A.J. Miller, D. Teitelbaum, R. Arnon and M. Sela. *Ann. Neurol.* **11**, 317-319 (1982).
144. Anti-schistosome monoclonal antibodies of different isotypes - correlation with cytotoxicity.
S. Horowitz, R. Tarrab-Hazdai, Z. Eshhar and R. Arnon. *EMBO J.* **2**, 193-198 (1983).
145. Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: Characterization of the specificity.
G.M. Bahr, Z. Eshhar, R. Ben-Yitzhak, F.Z. Modabber, R. Arnon, M. Sela and L. Chedid. *Mol. Immunol.* **20**, 745-752 (1983).
146. Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM.
E. Hurwitz, R. Kashi, D. Burowsky, R. Arnon and J. Haimovich. *Intl. J. Cancer* . **31**, 745-748 (1983).
147. A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
E. Hurwitz, R. Arnon, E. Sahar and Y. Danon. *Ann. N.Y. Acad. Sci.* **417**, 125-136 (1983).
148. Antibodies against synthetic peptides of the B subunit of cholera toxin: cross reaction and neutralization of the toxin.
C.O. Jacob, M. Sela and R. Arnon. *Proc. Natl. Acad. Sci.*, **80**, 7611- 7615 (1983).
149. The consequences of new approaches in parasitological research.
R. Arnon and M. Sela. In "*Parasitology A Global Perspective*". K.S. Warren and J.S. Bowers, eds. Springer Verlag, 246-255 (1983).

150. Clinical trials of a synthetic polypeptide (Copolymer 1) for the treatment of multiple sclerosis.
M.B. Bornstein, A.T. Miller, S. Slagle, V. Spada, R. Arnon, M. Sela and D. Teitelbaum, Proc. of the 25th Anniversary Symposium of the Belgian Research Group for Multiple Sclerosis. Brussels, April 1983.

151. Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of the hemagglutinin. M. Shapira, M. Jibson, G.M. Muller and R. Arnon. *Proc. Natl. Acad. Sci.* **81**, 2461-2465 (1984).
152. Anti-influenza synthetic vaccine. R. Arnon and M. Shapira. In "*Cold Spring Harbor Symposium on Modern Approaches to Vaccines*". M. Chanock and R. Lerner eds. Cold Spring Harbor Laboratory. 109-113 (1984).
153. Synthetic approaches to vaccination against bacterial toxins. M. Sela, C.O. Jacob and R. Arnon. In "*Modern Approaches to vaccines*". M. Chanock and R. Lerner Eds. Cold Spring Harbor Laboratory. 109-113 (1984).
154. Acetylcholinesterase of *Schistosoma mansoni*: antigenic cross-Reactivity with *Electrophorus electricus* and its functional implications. R. Tarrab-Hazdai, F. Levi-Schaffer, M. Smolarsky and R. Arnon. *Eur. J. Immunol.* **14**, 205-209 (1984).
155. Defect of human growth hormone receptors in the liver of two patients with Laron-type Dwarfism R. Eshet, Z. Laron, A. Pertzalan, R. Arnon and M. Dintzman. *Israel J. ed. Sci.* **20**, 8-11 (1984).
156. Differences among individual CEA preparations and carcinomas of Different origin as detected by monoclonal anti-CEA antibodies. Z. Eshhar, R. Ben-Itzhak, N. Ariel and R. Arnon. *Protides Biol. Fluids.* **31**, 929-932 (1984).
157. Neutralization of heat-labile toxin of *E. coli* by antibodies to Synthetic peptides derived from the B subunit of cholera toxin. C.O. Jacob, M. Pines and R. Arnon. *EMBO J.* **3**, 2889-2893 1 (984).
158. Both cholera toxin-induced adenylate cyclase activation and cholera toxin biological activity are inhibited by antibodies against related synthetic peptides. C.O. Jacob, M. Sela, M. Pines, S. Hurwitz and R. Arnon. *Proc. Natl. Acad. Sci.* **81**, 7893-7896 (1984).
159. Effect of phosphonium salts and phosphoranes on the acetylcholinesterase activity and on the viability of *Schistosoma mansoni* parasites. F. Levi-Schaffer, R. Tarrab-Hazdai, H. Meshulam and R. Arnon. *Int. J. Immunopharmacol.* **6**, 619-627 (1984).
160. Isolation and partial characterization of the tegumental outer membrane of schistosomula of *Schistosoma mansoni*. Levi-Schaffer, F., R. Tarrab-Hazdai, M.D. Schryer, R. Arnon and M. Smolarsky. *Mol. Biochem. Parasitol.* **13**, 283-300 (1984).

161. Acetylcholinesterase of *Schistosoma mansoni*: molecular forms of the solubilized enzyme.
R. Tarrab-Hazdai, F. Levi-Schaffer, G. Gonzales and R. Arnon.
Biochim. Biophys. Acta. **790**, 61-69 (1984).

162. The covalent linking of two nucleotide analogues to antibodies.
E. Hurwitz, R. Kashi, R. Arnon, M. Wilchek and M. Sela. *J. Med. Chem.* **28**, 137-140 (1985).
163. Biologically active antibodies elicited by a synthetic circumsporozoite peptide of plasmodium knowlesi administered in saline with a muramyl dipeptide derivative.
Clough, ER., Françoise MA., Barnwell, JW., Schlesinger, DH., Arnon, R., and Chedid, LA. *Infection and Immunity.* **48**, 839-842 (1985).
164. Specificity and cross-reactivity of synthetic peptides derived from a major antigenic site of influenza hemagglutinin.
M. Shapira, Z. Misulovin and R. Arnon. *Mol. Immunol.* **22**, 23-28 (1985).
165. Identification of *Schistosoma mansoni* antigens by means of biologically active monoclonal antibodies.
S. Horowitz, and R. Arnon. *Mol. Biochem. Parasitol.* **15**, 115-127 (1985).
166. In vivo protection against *S. mansoni* infection by monoclonal antibodies. S. Horowitz, V. Brenner and R. Arnon. *Immunol. Lett.* **9**, 69-73 (1985).
167. Protective Monoclonal Antibody Against *Schistosoma mansoni*.
R. Tarrab-Hazdai, F. Levi-Schaffer, V. Brenner, S. Horowitz, Z. Eshhar and R. Arnon. *J. Immunol.* **135**, 2772-2779 (1985).
168. Some properties of the plasma hGH activity in patients with Laron-type dwarfism determined by a radioreceptor assay using human liver tissue.
R. Eshet, S. Peleg, Z. Josefsberg, C. Fuchs, R. Arnon, and Z. Laron. *Hormone Research.* **22**, 276-283 (1985).
169. A synthetic vaccine against influenza with built-in adjuvanticity.
M. Shapira, M. Jolivet and R. Arnon. *Int. J. Immunopharmacol.* **7**, 719-723 (1985).
170. Priming immunization against cholera toxin and *E. coli* heat-labile toxin by cholera toxin short peptide - β -galactosidase hybrid synthesized in *E. Coli*.
C.O. Jacob, M. Leitner, A. Zamir, D. Salomon, and R. Arnon. *EMBO J.* **4**, 3339-3343 (1985).
171. Effect of Carrier on the Immunogenic Capacity of Synthetic Cholera Vaccine
C.O. Jacob, R. Arnon, and M. Sela. *Mol. Immunol.* **22**, No. 12, 1333-1339 (1985).
172. *Schistosoma mansoni*: Killing of transformed schistosomula by the alternative pathway of human complement.
M. Marikovsky, F. Levi-Schaffer, R. Arnon and Z. Fishelson. *Exp. Parasitol. Experimental Parasitology.* **61**, 86-94 (1986).
173. Acetylcholinesterase of *Schistosoma mansoni*: Purification and characterization.
Goldlust, R. Arnon, I. Silman and R. Tarrab-Hazdai. *J. Neuroscience*

- Res.* **15**, 569-581 (1986).
174. Ion fluxes changes during early stages of *S. mansoni*: Evaluation of complement effect.
R. Tarrab-Hazdai, R. Sagi-Eisenberg, V. Brenner and R. Arnon.
Europ. J. Biochem. **154**, 563-568 (1986).
 175. Priming immune response to cholera toxin induced by synthetic peptides.
C.O. Jacob, S. Grossfeld, M. Sela and R. Arnon. *Eur. J. Immun.*
16, pp. 1057-1062 (1986).
 176. Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins.
C.O. Jacob, I. Harari, R. Arnon and M. Sela. *Vaccine.* pp. **95-98** (1986).
 177. Immunity to heat-labile enterotoxins of porcine and human *Escherichia coli* strains achieved with synthetic cholera toxin peptides.
C.O. Jacob., R. Arnon, and R. A. Finkelstein. *Infection and Immunity.* **52**,
p. 562-567 May, (1986).
 178. Monoclonal and polyclonal antibodies against acetaldehyde containing epitopes in acetaldehyde-protein adducts.
Yedy Israel, Esther Hurwitz, Onni Niemela and Ruth Arnon. *Proc. Natl. Acad. Sci.* **83**, 7923-7927 (1986).
 179. Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. I. Preparation and characterization.
B. Schechter, R. Puzner, R. Arnon and M. Wilchek. *Cancer Biochem. Biophys.* **8**, 277-287 (1986).
 180. Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents: II. In-vitro and in-vivo activity.
B. Schechter, R. Puzner, M. Wilchek and R. Arnon. *Cancer. Biochem. Biophys.* **8**, 289-298 (1986).
 181. A novel lipid-conjugated marker for the direct labeling of the Schistosomula membrane.
F. Levi-Schaffer, R. Tarrab-Hazdai, R. Arnon and M. Smolarsky.
Am. J. Trop. Med. Hyg. **35**, 544-548 (1986)
 182. Mucosal and Systemic antibodies against cholera toxin induced by Peyer's patch Immunizations with a Synthetic Peptide conjugated to tetanus toxoid.
J.P.Vaerman, R. Arnon and C. O. Jacob. *Protides of the Biological Fluids.* A. 4. Immunological Topics. **34**, pp. 189-192 (1986).
 183. Anti-cholera response elicited by a completely synthetic antigen with built-in adjuvanticity administered in aqueous solution.
Chaim O. Jacob, Ruth Arnon and Michael Sela.
Immun. Lett **14** . 43-48 (1986/87).
 - 183a.Role of cellular and humoral immunity and helper cell involvement

- in permissiveness to infection by *Schistosoma mansoni*.
F. Mendelovic, R. Tarrab-Hazdai and R. Arnon. *Eur. J. Immunol.* **17**, 1151-1157 (1987).
183. Selective cytotoxicity against tumor cells by cis-platinun complexed to antitumor antibodies via carboxymethyl dextran.
B. Schechter, R. Pauzner, R. Arnon, J. Haimovich and M. Wilchek. *Cancer Immunol. Immunother.* **25**, 225-230 (1987).
184. Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic and against a murine carcinoma.
B. Schechter, M. Wilchek. and R. Arnon. *Int. J. Cancer.* **39**, 409-413 (1987).

187. Investigacion basica en inmunologia y su impacto en la lucha contra la enfermedad.
Ruth Arnon. *Publicado en la Revista Clinica Espanola*. **180**, Num 2. 93-99 (1987).
188. Proteases secreted by transforming schistomula of *Schistosoma mansoni* promote resistance to killing by complement.
M. Marikovsky, R. Arnon and Z. Fishelson. *J. of Immunol.* **141**, 273-278 (1988).
189. Purification and characterization of proteases secreted by transforming schistosomula of *Schistosoma mansoni*. Moshe Marikovsky, Zvi Fishelson, and Ruth Arnon. *Mol. Biochem. Parasitol.* **30**, 45-54 (1988).
190. A pilot trial of COP 1 in exacerbating -remitting multiple sclerosis.
Murray Bornstein, Aaron Miller, Susan Slagle, Muriel Weitzman, Howard Crystal, Ellen Drexler, Marshall Keilson, Arnold Merriam, Sylvia Wassertheil-Smolle, Vincent Spada, Ruth Arnon, Israel Jacobsohn, and Michael Sela. *The New England Journal of Medicine.* **317**, 408-414 (1987).
191. Acetylcholinesterase of *S.mansoni* An antigen of functional implications.
Ruth Arnon, Berta-Espinoza-Ortega and Rebeca Tarrab-Hazdai.
In: "*Memorias do Instituto Oswaldo Cruz*". Vol. **82**, Suppl. IV: 163-170 1987.
192. Reduction of cytotoxicity to host by new scheduling policies of phase-specific drugs.
Z. Agur, R. Arnon and B. Schechter. *Math. Biosci.* **92**, 1-15 (1988)
193. NMR study of the complexes between a synthetic peptide derived from the B subunit of cholera toxin and three monoclonal antibodies against it.
Jacob Anglister, Olga Assulin, Gil Ast, Rachel Pinker, Chaim Jacob and Ruth Arnon. *Biochemistry.* **27**, 717-724 (1988).
194. Isotype restriction of murine antibodies towards the loop region of hen's egg white lysozyme. Verschoor J.A., Van Vuuren K.J., Visser L., I. Pecht and R. Arnon. *Immunology Letters.* **17**, 21-28 (1988).
195. Synthetic peptides of Shiga toxin B-subunit induce antibodies which neutralize its biological activity.
Ilana Harari, Arthur Donohue-Rolfe, Gerald Keusch and Ruth Arnon, *Infection and Immunity.* **56**, 1618-1624 (1988).
196. Acetylcholinesterase in *S. mansoni* is anchored to the membrane via covalently attached phosphatidylinositol.
Berta Espinoza, R. Tarrab-Hazdai, I. Silman, and R. Arnon.
Biochem. Parasitol. **29**, 171-179 (1988).
197. Clinical experience with COP-1 in multiple sclerosis.
Murray B. Bornstein, A. Miller., S. Slagle., M. Weitzman., H. Crystal., E. Drexler., M. Keilson., A. Merriam., S. Wassertheil-Smolle., V. Spada., W. Weiss., R. Arnon., I. Jacobsohn., D. Teitelbaum., and M. Sela. *Neurology.* **38**, (Suppl 2). 66-69 (1988).

198. Specific Inhibition of T Cell Response to Myelin Basic Protein by the Synthetic Copolymer-Cop 1.
D. Teitelbaum, R. Aharoni, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci. USA* **85**, 9724-9728 (1988).

199. Clinical trial of Cop 1 in chronic-progressive multiple sclerosis. A. Miller, M. Bornstein, S. Slagle, H. Crystal, E. Drexler, M. Keilson, V. Spada, W. Weiss, M. Weitzman, S. Appel, S. Brown, L. Rolak, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela. *Neurology*. **39**, (Suppl. 1), 356 (1988).

200. Suppression of demyelinating diseases by synthetic copolymers.
R. Arnon and D. Teitelbaum. In: *Multidisciplinary Approach to Myelin Diseases*". Ed. Q.S. Crescenzi. Plenum Publ. Corp. p. 243 (1988)

201. Blood levels and serum-protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.
Bilha Schechter, Mark A. Rosing, Meir Wilchek and Ruth Arnon. *Cancer Chemother. Pharmacol.* **24**, 161-166 (1989).

202. Soluble polymers as carriers of Cis-platinum.
B. Schechter, A. Neumann, M. Wilchek, and R. Arnon. *Journal of Controlled Release*. **10**, 75-87 (1989).

203. Targeted and Polymer-Conjugated Drug Systems
M. Wilchek, B. Schechter and R. Arnon. In: *Macromolecular Proteins*. **189** (1989).

204. Expression of Shiga toxin epitopes in *E. coli* immunological characterization.
J. McEwen, M. Leitner, I. Harari and R. Arnon. *Immunology Letters*. **21**, 157-164 (1989).

205. Genetic control of immune response to a purified *Schistosoma mansoni* antigen: I. Effect of MHC Class II Antigens on the cellular, humoral, and rotective responses.
F. Mendlovic, R. Tarrab-Hazdai, J. Puri, and R. Arnon. *Parasite Immunology*. **11/6**, 667-682 (1989).

206. Genetic control of immune response to a purified *Schistosoma mansoni* antigen: II. Establishment and Characterization of Specific I-A and I-E restricted T-cell clones.
F. Mendlovic, R. Arnon, R. Tarrab-Hazdai, and J. Puri. *Parasite Immunology*. **11/6**, 683-694 (1989).

207. Immunological studies on one defined protein region. The "loop" of Lysozyme.
R. Arnon, M. Sela and I. Pecht. In: *The Immune Response to Structurally Defined Proteins: The Lysozyme Model*. Eds. S. Smith-Gill and E. Sercarz. Adenine Press. pp **315-323** (1989).

208. Synthetic antigens and vaccines.
R. Arnon. In: *Immunological adjuvants and vaccine*. Edited by G. Gregoriadis, A. C. Allison, and G. Poste. Nato ASI Series A: Life Sciences, Vol. **179**, Plenum Press, N.Y. 175-185 (1989).
209. Suppression of experimental allergic encephalomyelitis by Cop 1 - relevance to multiple sclerosis.
R. Arnon, D. Teitelbaum and M. Sela. *Isr. J. Med. Sci.* **25**, pp. 686-689 (1989).
210. Clinical trial of Copolymer 1 in multiple sclerosis.
D. Teitelbaum, R. Arnon, M. Sela and O. Abramsky. *Harefuah*. CXVI: **453** (1989).
211. The use of antibodies and polymers as carriers of cytotoxic drugs in the treatment of cancer. In: *Horizons in Biochemistry and Biophysics*".
R. Arnon, E. Hurwitz and B. Schechter. Drug Carrier Systems. Volume Editors: F. H. Roerdink and A.M. Kroon. Series Editors: E. Quagliariello and F. Palmieri. Wiley and Sons, Ltd. England. Vol. **9**. p. 33 (1989).
212. Complement regulation on the surface of cultured schistosomula and adult worms of *S. Mansoni*.
M. Marikovsky, M. Parizade, R. Arnon and Z. Fishelson. *Eur. J. Immunol.* **20**, 221-227 (1990)
213. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin.
B. Schechter, R. Silberman, R. Arnon and M. Wilchek. *Eur. J. Biochem.* **189**, 327-331 (1990).
214. Life span of parasite in Schistosomiasis patients.
R. Arnon. *Israel J. of Medical Sciences.* **26**, 404-405 (1990).
215. A new method for reducing cytotoxicity of AZT to the bone-marrow.
Z. Agur, R. Arnon, B. Sandak and B. Schechter. Extracted from the Proceedings of the 16th International Congress of Chemotherapy, June, 1989, Israel. pp 4621-4622 (1990).
216. Carboxy-terminal peptides from the B-subunit of shiga toxin induce a local and parenteral protective effect.
I. Harari and R. Arnon. *Molecular Immunology.* **27**, 7, 613-631 (1990).
217. *Schistosoma mansoni*: Localization of the 28kDa secreted protease in cercaria.
Marikovsky, M., Arnon, R. and Fishelson, Z. *Parasite Immunology.* **12**, 389-401 (1990).
218. Suppressive activity of Cop-1 in EAE and its Relevance to Multiple Sclerosis.
M. Sela, R. Arnon and D. Teitelbaum. *Bull. Inst. Pasteur.* **88**, 303-314 (1990).
219. Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis.

- M. Sela, R. Arnon and D. Teitelbaum. *Bull. Inst. Pasteur.* **88**, 303 (1990).
220. Phosphatidylinositol-specific phospholipase C induces biosynthesis of acetylcholinesterase via diacylglycerol in *Schistosoma mansoni*.
B. Espinoza, I. Silman, R. Arnon and R. Tarrab-Hazdai. *Eur. J. Biochem.* **195**, 863-870 (1991).
221. A Placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.
M.B. Bornstein, A. Miller, S. Slagle, M. Weitzman, E. Drexler, M. Keilson, V. Spada, W. Weiss, S. Appel, L. Rolak, Y. Harati, S. Brown, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela. *Neurology.* **41**, 533-539 (1991).
222. Acetylcholinesterase from *Schistosoma mansoni*: immunological characterization.
B. Espinoza, R. Tarrab-Hazdai, S. Himmeloch and R. Arnon. *Immunology Letts.* **28**, 167-174 (1991).
223. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex.
R. Aharoni, D. Teitelbaum, R. Arnon and J. Puri. *Nature.* **351**, No. **6322**, 147-150 (1991).
224. Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the Avidin-Biotin system.
B. Schechter, R. Arnon, M. Wilchek, J. Schlessinger, E. Horwitz, E. Aboud-Pirak and M. Sela. *Int. J. Cancer.* **48**, 167-172 (1991).
225. Zidovudine toxicity to murine bone marrow may be effected by the exact frequency of drug administration.
Z. Agur, R. Arnon, B. Sandak and B. Schechter. *Exp. Hematol.* **19**, 364-368 (1991).
226. Synthetic peptides as the basis for vaccine design.
Ruth Arnon. *Mol. Immun.* **28**, No. 3, 209-215 (1991).
227. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.
D. Teitelbaum, R. Aharoni, M. Sela and R. Arnon. *Proc. Natl. Acad. Sci. USA* **88**, 9528-9532, (1991).
228. Specific inhibition by the synthetic copolymer Cop-1 of human T cell lines specific to myelin basic protein.
Dvora Teitelbaum, Ron Milo, Ruth Arnon and Michael Sela. *J. of Neuroimmunology.* **Supplement 1** (Abstracts) p **72** (1991).
229. Complexes and conjugates of Cis-Pt for immunotargeted chemotherapy.
R. Arnon, B. Schechter and M. Wilchek. In: *Immunology of Proteins and Peptides*. Ed: Atassi, M.Z. (Ed). Plenum Press. New York. **VI**: 79-90 (1991).
230. Synthetic recombinant vaccine expressing influenza Haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice.
A. McEwen, R. Levi, R. J. Horwitz and R. Arnon. *Vaccine.*

- 10, 405-411 (1992).
231. Synthetic Copolymer 1 inhibits human T-cell lines specific for myelin basic protein. D. Teitelbaum, R. Milo, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci.* **89**, 137-141 (1992).
232. Antibodies to Shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shiga dysentery. M. Levine, J. McEwen, G. Losonsky, M. Reymann, I. Harari, J. E. Brown, D.N. Taylor, A. Donohue-Rolfe, D. Cohen, M. Bennish, Y. L. Lim and R. Arnon. *J. of Clinical Microbiology.* 30, No 7. pp **1636-1641** (1992).
233. Effect of the dosing interval in myelotoxicity and survival in mice treated by cytarabine. Z. Agur, R. Arnon and B. Schechter. *Eur. J. Cancer.* **28A**, 1085-1090 (1992).
234. Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in-vitro immunotrargeting via biotinyl monoclonal antibody. B. Schechter, R. Arnon, M. Wilchek. *Cancer Research.* **52**, 4448-4452 (1992).
235. Peptide binding to Class I molecules of the major histocompatibility complex on the surface of living target cells. U. Kubitscheck, R. Levi, R.J. Horwitz, R. Arnon and I. Pecht. *Scand. J. Immunol.* **36**, 341-348 (1992).
236. T-suppressor hybridomas and IL-2 dependent lines induced by Copolymer 1 or by spinal cord homogenate downregulate experimental allergic encephalomyelitis. R. Aharoni, D. Teitelbaum and R. Arnon. *Eur. J. Immunol.* **23**, 17-25 (1993).
237. On the existence of suppressor cells. R. Arnon, D. Teitelbaum. *Int. Archives of Allergy & Immunology.* **100**, 2-7 (1993).
238. Immunogenicity and efficacy of oral or intranasal *S. flexneri* 2a and *S. sonnei* Proteosome-LPS vaccines in animal models. N. Orr, G. Robin, D. Cohen, R. Arnon and G.H. Lowell. *Infection and Immunity.* **61**, 2390-2395 (1993).
239. Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE. Y. Shoenfeld, M. Blank, R. Aharoni, D. Teitelbaum, R. Arnon. *Immunology Lets.* **36**, 109-116 (1993).
240. The amount of acetylcholinesterase on the parasite surface reflects the differential sensitivity of schistosome species to metrifonate. M. Camacho, R. Tarrab-Hazdai, B. Espinoza, R. Arnon and A. Agnew. *Parasitology.* **108**, 153-160 (1994).
241. Immunospecific drug design - prospects for treatment of autoimmune diseases. R. Arnon and D. Teitelbaum. *Therapeutic Immunology.* **1**, 65-70 (1994).

242. *Schistosoma mansoni*: Isolation and characterization of Smpi56, a novel serine protease inhibitor.
Y. Ghendler, R. Arnon and Z. Fishelson. *Exper. Parasitology*. **78**, 121-129 (1994).
243. Anti-nuclear antibodies associated with schistosomiasis and anti-schistosomal antibodies associated with SLE.
Rahima, D., Tarrab-Hazdai, R., Blank, M., Arnon, R. and Shoenfeld. *Y. Autoimmunity*. **17**, 127-141 (1994).
244. Functional and antigenic similarities between a 94 kDa protein of *Schistosoma mansoni* (SCIP-1) and human CD59.
M. Parizade, R. Arnon, P.J. Lachmann and Z. Fishelson. *J. Exp. Medicine*. **179**, 1625-1636 (1994).
245. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells - specificity and promiscuity.
M. Fridkis-Hareli, D. Teitelbaum, E. Gurevich, I. Pecht, C. Brautbar, O. J. T. Kwon Brenner, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci. USA*. **91**, 4872-4876 (1994).
246. Enhancement of anti-*Shigella* Lipopolysaccharide (LPS) Response by addition of the Cholera Toxin B Subunit to Oral and Intranasal Proteosome-*Shigella flexneri* 2a LPS Vaccines. N. Orr, R. Arnon, G. Rubin, D. Cohen, H. Bercovier and G. Lowell.
Infection and Immunity. **62**, 5198-5200 (1994).
247. Microculture virus titration (MCVT)- a simple colorimetric assay for influenza virus titration. R. Levi, T. Beeor-Tzahar and R. Arnon. *J. of Virological Methods*. **52**, 55-64 (1994).
248. Polymers in drug delivery: Immunotargeting of carrier-supported cis-platinum (CDDP) complexes.
B. Schechter, R. Arnon and M. Wilchek. *Reactive Polymers*. **25**, 167-175 (1995).

249. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to Class II major histocompatibility complex molecules on living antigen presenting cells.
M. Fridkis-Hareli, D. Teitelbaum, R. Arnon and M. Sela. *Cellular Immunology*. **163**, 229-236 (1995).
250. Stage-specific expression of the mRNA encoding a 14-3-3 protein during the life cycle of *Schistosoma mansoni*.
D. Schechtman, D. Ram, R. Tarrab-Hazdai, R. Arnon and I. Schechter. *Molecular and Biochemical Parasitology*. **73**, 275-278 (1995).
251. Renal accumulation of streptavidin: potential use for targeted therapy of the kidney.
B. Schechter, R. Arnon and M. Wilchek. *Kidney International*. **47**, 1327-1335 (1995).
252. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes.
R. Levi, E. Aboud-Pirak, C. Leclerc, G.H. Lowell, and R. Arnon. *Vaccine*, **13**, 1353-1359 (1995).
253. Synthetic recombinant vaccines against viral agents.
R. Arnon and R. Levi. *Int. Arch. Allergy Immunol.* **108**, 321-326 (1995).
254. Monoclonal antibodies against acetylcholinesterase of *Schistosoma mansoni*: Production and characterization.
B. Espinoza, M. Parizade, E. Ortega, R. Tarrab-Hazdai, D. Zilberg and R. Arnon. *Hybridoma*. **14**, 577-586 (1995).
255. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens *in vitro* and confers the capacity to prevent murine graft-versus-host disease *in vivo*.
P. Schlegel, R. Aharoni, Y. Chen, J. D. Teitelbaum, R. Arnon, M. Sela, and N.J. Chao. *Proc. Natl. Acad. Sci. USA*. **93**, 5061-5066 (1996).
256. New insights into the mechanism of action of Copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.
R. Arnon, M. Sela and D. Teitelbaum. *J. Neurol.* **243**, Supl. 1. S8-S13 (1996).
257. *Schistosoma mansoni*: evidence for a 28-kDa membrane-anchored protease on schistosomula.
Y.Ghendler., M. Parizade., R. Arnon., J.H.. McKerrow and Z. Fishelson. *Experimental Parasitology*. **83**, 73-82 (1996).
258. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of Copolymer-I induced disease.
A. Ben-Nun., I. Mendel, R. Bakimer, M. Fridkis-Hareli, D. Teitelbaum, R. Arnon., M. Sela and N. Kerlero de Rosbo. *J. Neurol.* **243**, (suppl 1) S14-S22 (1996).
259. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection.

- R. Levi and R. Arnon. *Vaccine*. **14**, No. 1, 85-92 (1996).
260. Liver accumulation of TNP-modified Streptavidin and Avidin: Potential use for Targeted Radio-and Chemotherapy.
B. Schechter, R. Arnon, Y.E. Freedman, L. Chen and M. Wilchek.
J. Drug. Targeting. **4**, No. 3, 171-179 (1996).
261. Differential reactivities of the *Arachis hypogaea* (peanut) and *Vicia villosa* B4 lectins with human ovarian carcinoma cells grown in either *in vitro* or *in vivo* xenograft model.
D. Avichezer, R. Arnon. *FEBS LTRS*. **395**: 103-108 (1996).
262. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.
D. Teitelbaum, M. Fridkis-Hareli, R. Arnon and M. Sela. *J. of Neuroimmunology*. **64**, 209-217 (1996).
263. Relationship between antigenicity and immunogenicity of chimeric Hepatitis B virus core particles carrying HIV-type epitopes.
E. Grene, G. Mezule, G. Borisova, P. Pumpens, Z. Bentwich and R. Arnon. *AIDS Research and Human Retroviruses*. Vol **13**, No 1, 41-51 (1997).
264. Modulation of the immune response in multiple sclerosis: Production of monoclonal antibody specific to HLA/Myelin basic protein.
J. Puri, R. Arnon, E. Gurevich and D. Teitelbaum. *The J. of Immunol*. **158**, 2471-2476 (1997)
265. Synthetic vaccines based on peptides, oligonucleotides and conjugate antigens.
R. Arnon. *Behring Inst. Mitt*. **98**, 184-190 (1997).
266. Immunoreactivities of polyclonal and monoclonal anti-T (Thomsen-Friedenreich) and -Tn antibodies with human carcinoma cells, grown *in vitro* and in a xenograft model).
D. Avichezer, G. F. Springer, B. Schechter, and R. Arnon. *Int. J. of Cancer*. **72**, 119-127 (1997).
267. Binding of Copolymer I and myelin basic protein leads to clustering of class II major histocompatibility complex molecules on antigen-presenting cells.
M. Fridkis-Hareli, D. Teitelbaum, I. Pecht, R. Arnon and M. Sela. *Int. Immunol*. **9**, 925-934 (1997).
268. Studies on the mechanism and specificity of the effect of the synthetic random Copolymer GLAT on graft-versus-host disease.
R. Aharoni, P.G. Schegel, D. Teitelbaum, O. Roikhel-Karpov, Y. Chen, R. Arnon, M. Sela and N. J. Chao. *Immunol. Letts*. **58**, 79-87 (1997).
- 268a. Specificity of the suppressive effect of copolymer 1.
D. Teitelbaum., T. Ben-Yedidia T., R. Tarrab-Hazdai., N. Orr., R. O. Kaprov-Roikhal. And R. Arnon. *J. Neurol*. **1996**: 243 (suppl 2.)S85
269. Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

- R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon. *Proc. Natl. Acad. Sci.* **94**, 10821-10826 (1997).
270. Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates - effect on human ovarian carcinoma. D. Avichezer, B. Schechter, R. Arnon. *Reactive and Functional Polymers.* **36**, 59-69 (1998).
271. Activation of influenza-specific memory cytotoxic T lymphocytes by concanavalin A stimulation. M. Tsotsiashvilli, R. Levi, R. Arnon and Gideon Berke. *Immun. Letts.* **60**, 89-95 (1998).
272. Efficacy of anti-influenza peptide vaccine in aged mice. T. Ben-Yedidia, L. Abel, R. Arnon and A. Globerson. *Mechanisms of Ageing And Development.* **104**, 11-23 (1998)
273. Synthesis and characterization of a protective peptide-based vaccine against *Schistosma Mansoni*. R. Tarrab-Hazdai, D. Schechtman and R. Arnon. *Infection & Immunity* **66**, 4526-4530 (1998)
274. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. T. Ben-Yedidia and R. Arnon. *Immunol. Letts.* **64**, 9-15 (1998).
275. A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. D. Avichezer, J. Taylor-Papadimitriou and R. Arnon. *Cancer Biochem. Biophys.* **16**, 113-128 (1998.)
276. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by Copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon. *J. of Neuroimmunology.* **91**, 135-146 (1998).
277. Synthetic peptide-based vaccines against influenza. T. Ben-Yedidia and R. Arnon. *Letters in Peptide Science.* **5**, 341-344, (1998).
278. The chemistry of Copaxone drug. M. Sela and R. Arnon. *Chemicals in Israel.* **1**, (1999).
279. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci, USA.* **96**, 634-639, (1999).
280. Development of Copolymer 1 (Copaxone®) as a specific drug against Multiple Sclerosis. D. Teitelbaum, R. Aharoni, M. Fridkis-Hareli, R. Arnon and M. Sela. In: "*The decade of autoimmunity.* (Ed) J. Shoenfeld. Elsevier Science, B.V. 191-196, (1999).
281. Immunomodulation of experimental autoimmune encephalomyelitis

- by oral administration of Copolymer 1.
D. Teitelbaum, R. Arnon and M. Sela. *Proc. Natl. Acad. Sci.* 3842-3847, (1999).
282. Proteosome delivery of a protective 9B-antigen against *Schistosoma mansoni*.
R. Tarrab-Hazdai, D. Schechtman, G. Lowell, E. Pirak and R. Arnon. *Int. J. of Immunopharmacology*. **21**: 205-218, (1999)
283. Binding of random copolymers of three amino acids to class II MHC molecules.
M. Fridkis-Hareli, R. Aharoni, D. Teitelbaum, R. Arnon, M. Sela and J. Strominger. *Int. Immunol.* **11**: No 5, 635-641, (1999).
284. Organ selective delivery using a tissue-directed streptavidin-biotin System: Targeting 5-fluorouridine via TNP-streptavidin.
B. Schechter, L. Chen, R. Arnon and M. Wilchek. *J. of Drug Targeting*. **6**, 337-348, (1999).
285. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection.
T. Ben-Yedidia, H. Marcus, Y. Reisner and R. Arnon. *Int. J. Immunol.* **11**, No 7. 1043-1051, (1999).
286. Acetylcholinesterase from *Schistosoma mansoni*: interaction of globular species with heparin, by R. Tarrab-Hazdai, Lilly Toker, Israel Silman, and R. Arnon. *Biochemical Journal*. **344** (3), 945-951, (1999)
287. Acetylcholinesterase of *Shistosoma mansoni* - Functional Correlates.
Ruth Arnon, Israel Silman and Rebeca Tarrab-Hazdai. *Protein Science*. 2553-2561, (1999)
288. Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by *Schistosoma mansoni*.
T. Ben-Yedidia, R. Tarrab-Hazdai, D. Schechtman and R. Arnon. *Infec. Immunity*. **67** (9), 4360-4366, (1999).
289. Specific TH2 cells accumulate in the central nervous system of mice protected against EAE by Copolymer 1.
Rina Aharoni, Dvora Teitelbaum, Orith Leitner, Asher Meshorer, Michael Sela and Ruth Arnon. *PNAS*. **97**, (21) 11472-11477, (2000)
290. A mimotope peptide-based vaccine against *Schistosoma Mansoni* synthesis and characterization.
R. Arnon, R. Tarrab-Hazdai and M. Steward. *Immunology*. **101** (4): 555-562, (2000)
291. Humoral and cellular immune response in MS patients treated with Copaxone®.
Telma Brenner, Ruth Arnon, Michael Sela, Oded Abramsky, Zev Meiner, Rivka Riven-Kreitman, Nora Tarcik, Dvora Teitelbaum. *J. of Neuroimmunology*. **115**, 152-160 (2001)
292. The 14-3-3 protein as a vaccine candidate against *schistosomiasis*¹.
Deborah Schechtman, Rebecca Tarrab-Hazdai and Ruth Arnon *Parasite Immunology*. **23**: 213-217 (2001)

293. Copolymer 1 inhibits manifestations of graft rejection
R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela.
Transplantation, **72**: No 4, 598-605 (2001)
294. Peptide-based synthetic recombinant vaccines with anti-viral efficacy.
R. Arnon, R. Tarrab-Hazdai and T. Ben-Yedidia. *Biologicals*, **29**, 237- 242. (2001)
295. Expression and immunolization of the 14-3-3 protein of *Schistosoma mansoni*.
D. Schechtman, R. Winnen, R. Tarrab-Hazdai, D. Ram,
V. Shinder, C. Grevelding, W. Kunz and R. Arnon. *Parasitology*, **123**,
573-582. (2001)
296. Oral treatment of mice with Copolymer 1 (Glatiramer Acetate)
results in the accumulation of specific TH2 cells in the central nervous system.
Rina Aharoni, Asher Meshorer, Michael Sela and Ruth Arnon.
J. of Neuroimmunology, **126** 58-68 (2002).
297. Intranasal immunization with synthetic recombinant vaccine
containing multiple epitopes of influenza virus.
Sung Ho Jeon, Tamar Ben-Yedidia and Ruth Arnon. *Vaccine*, 20/21-**22**. 2772-2780.
(2002)
298. Immunization with influenza virus haemagglutinin globular region
containing the receptor-Binding Pocket.
Sung Ho Jeon and Ruth Arnon. *Viral Immunology*, **15**: 165-176. (2002).
299. Therapeutic vaccines – realities of today and hopes for the future.
Michael Sela, Ruth Arnon and Bilha Schechter. *Drug Discovery
Today*, **7**, 664-673, (2002).
300. A retro-inverso peptide analogue of influenza virus hemagglutinin
B-cell epitope 91-108 induces a strong mucosal and systemic immune response
and confers protection in mice after intranasal immunization.
Tamar Ben-Yedidia, Anne- Sophie Beignon, Charalambos D. Partidos,
Sylviane Muller and Ruth Arnon. *Molecular Immunology*, **39** 232-331 (2002)
301. The Concept of Specificity in Peptide Vaccines for Infectious Autoimmune
and Neoplastic Diseases.
Michael Sela and Ruth Arnon. In: *“Life Sciences for the 21st Century”*
(E. Keinan, I. Schechter, M. Sela (Eds). Wiley.VCH. 225-258. (2003).
302. Old and new vaccine approaches.
Ruth Arnon and Tamar Ben-Yedidia.
Int. Immunopharmacology **3** 1195-1204. (2003)
303. Glatiramer Acetate (Copaxone®) regulates nitric oxide and related
cytokine secretion in xperimental autoimmune encephalitis.
Basak Kayhan, Rina Aharoni and R. Arnon. *Immun. Letts.* **88**, 185-192 (2003)
304. Immunomodulation by the Copolymer Glatiramer Acetate.
R. Arnon and M. Sela. *J. of Molecular Recognition.* **16**: 412-421 (2003)

305. Antibodies to glatiramer do not interfere with its biological functions and therapeutic efficacy" by D. Teitelbaum, Talma Brenner, Oded Abramsky, Rina Aharoni, Michael Sela and Ruth Arnon. *Multiple Sclerosis* **9**, 592-599. (2003).
306. Glatiramer acetate specific T-cells in the brain express TH2/3 Cytokines and brain-derived neurotrophic factor in situ. Rina Aharoni, Basak Kayhan, Raya Eilam, Michael Sela and Ruth Arnon. *PNAS*. Vol 100. **24**, 14157-14162 (2003)
307. A DNA Aptamer prevents influenza infection by blocking the Receptor binding region of the viral haemagglutinin Sung Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia and Ruth Arnon. *J. Biol. Chem* 279: No **46**: pp 48410-48419 (2004)
308. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Ruth Arnon and Rina Aharoni. *PNAS* **101**, (Supplement) 14593-14598 (2004)
309. Oral Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis. Clinical and Immunological Studies. Dvora Teitelbaum, Rina Aharoni, Ety Klingler, Rivka Kreitman, Emanuel Raymond, Arthur Malley, Rona Shofti, Michael Sela and Ruth Arnon. *Ann. N.Y. Acad. Sci.* **1029**, 239-249 (2004)
310. Combined treatment of Glatiramer Acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Rina Aharoni, Alexander Yussim, Michael Sela, Ruth Arnon. *International Immunopharm.* **5**: pp 23-32 (2005)
311. Towards an epitope-based human vaccine for influenza. Tamar Ben-Yedidia and Ruth Arnon. *Human Vaccines*. Vol **1**. 3. 95-101. 2005.
312. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Rina Aharoni, Basak Kayhan, Ruth Arnon. *Inflam Bowel Disease*. **11**: 106-115 (2005)
313. Neurogenesis and Neuroprotection induced by peripheral immunodulatory treatment of experimental autoimmune encephalomyelitis. Rina Aharoni, Raya Eilam and Ruth Arnon *J. of Neuroscience*. **25** (36): 8217-8228. (2005).
314. Case History of Copaxone® - From the Bench to Bedside Dvora Teitelbaum*, Ruth Arnon and Michael Sela. *Comprehensive Medicinal Chemistry II*. Vol **8**: (in press 2005).

315. Ecto-and Exo -Protein kinases in *Schistosoma mansoni*: Regulation of surface phosphorylation by acetylcholine and identification of the alpha subunit of CKII as a major secreted protein kinase. Rebeca Tarrab-Hazdai, Tamar Hanoch, Sung Ho Jeon, Henya Pauli, Daniel Gold, Ruth Arnon and Rony Seger. *J. of Parasitol.* **91**, 756-763 (4) (2005)
316. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Rina Aharoni, Raya Eilam, Hagit Domev, Galya Labunskay, Michael Sela and Ruth Arnon. *PNAS.* **102**. 52: 19045-19050. (2005).
317. Immunomodulatory Therapeutic Effect of Glatiramer Acetate on Several Murine Models of Inflammatory Bowel Disease. Rina Aharoni, Basak Kayhan, Ori Brenner, Hagit Domev, Galya Labunskay and Ruth Arnon *J. of Pharmacology and Experimental Therapeutics.* **318**: No 1. 68-78. (2006).
318. Flagella as a Platform for Epitope-Based Vaccines. Tamar Ben-Yedidya and Ruth Arnon. *IMAJ.* **8**: 316-317. (2006).
319. Does glatiramer acetate induce neurogenesis in experimental autoimmune encephalomyelitis? Ruth Arnon. Supp.1, Barcelona *J. Neurol.* 254: 41-46. (2007).
320. Copaxone . D. Teitelbaum, R. Arnon and M. Sela *Comprehensive Medicinal Chemistry II.* (Editors-in-Chief John. B. Taylor and David J. Triggle). Vol 8: 173 -185. (2007).

321. Epitope-based vaccine against influenza.
T. Ben-Yedidia and R. Arnon. *"Expert Review of Vaccines" (ERV)* 6: (6); 939-948. 2007.
322. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Rina Aharoni, Hagar Sonogo, Ori Brenner, Raya Eilam and Ruth Arnon. *Immun. Letts.* **112**: (2): 110-119. (2007).
323. Reduction of established tumors in mice by recombinant flagella-MUC1 based Vaccine. *Vaccine*. Nathalie Moyellem, Ruth Arnon. (in preparation).
324. Demyelination arrest and remyelination induced by Glatiramer acetate treatment.
Rina Aharoni, Avia Herschkovitz, Raya Eilam, Michal Bloomberg, Michael Sela, Wolfgang Bruck and Ruth Arnon. *PNAS* 105: (32) 11358-11363. (2008)
325. A Universal epitope-based influenza vaccine and its efficacy against H5N1
Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, and Ben-Yedidia T. *Vaccine*. 2099-2107 (2009)
326. The Therapeutic Effect of TV-5010 in a Murine Model of Inflammatory Bowel Disease - Dextran Induced Colitis.
Rina Aharoni, Ori Brenner, Adva Cohen and Ruth Arnon. *International Immunopharmacology*. **8**: 1578-1588 (2008).
327. Immunomodulation and Neuroprotection. Can immunomodulatory treatment lead to effective neuroprotection and repair in the CNS?
Rina Aharoni and Ruth Arnon. 2008 (in preparation)
§
328. Preclinical efficacy of virus-like particle-based vaccine against avian influenza H5N1.
Ruth Arnon and Tamar Ben-Yedidia. *Future Microbiol.* **4**: (5): 503 (2009)
329. Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in the mouse model of multiple sclerosis, by Rina Aharoni, Elizabeta Aizman, Ora Fuchs, Ruth Arnon, David Yaffe and Rachel Sarig.
J. of Neuroimmunology. **30**: 73-83 (2009).
330. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
Rina Aharoni, Raya Eilam, Ariel Stock, Ania Vainshtein, Elias Shezen, Hilah Gal, Nir Friedman, Ruth Arnon. *J. of Neuroimmunology*. **225**: 100-111 (2010)
331. Glatiramer Acetate (GA, (Copolymer-1) an hypothetical treatment option for Rett syndrome.
B. Ben-Zeev, Rina Aharoni, A. Nissenkorn and Rina Aharoni. (submitted 2010)
332. The Beneficial Effect of Glatiramer Acetate Treatment on Syndecan-1 Expression in Dextran Sodium Sulfate Colitis .
Doron Yablecovitch., Maytal Shabat-Simon., Rina Aharoni., Raya Eilam., Ori Brenner and Ruth Arnon.

J. Pharmacol. Exp. Ther. **337**(2): 391-9 (2011)

333. Therapeutic Muc1-based vaccine expressed in flagella – Efficacy in an aggressive model of breast cancer.

Nathalie Moyal-Amsellem and R. Arnon. (in preparation) (2011)

334. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune encephalomyelitis and the neuroprotective effect of glatiramer acetate “.

Rina Aharoni, Anya Vainshtein, Raya Eilam, Ariel Stock, Renana From, Vera Shinder and Ruth Arnon (submitted for publication), *Journal of Autoimmunity*, 2011

B. Books Published

1. Synthetic vaccines. Vol I. & II.
R. Arnon, editor. CRC Press Inc. Boca Raton, Florida, (1987).
2. Copolymer 1 and related peptides as immunomodulating agents.
R. Arnon. Chapter in Martin & Kastin (eds) *Handbook of Biologically Active Peptides*. 2006.
3. Chapter (in book ed by Fabio Bagnoli (ed) in publication (2010)
4. **Peptides and Polypeptides as Immunomodulators and their Consequential Therapeutic Effect in Multiple Sclerosis and Other Autoimmune Diseases. (Santos)**
By Ruth Arnon, Michael Sela and Rina Aharoni (in preparation, 2010)

C. Review Articles

1. Antigenic properties of proteolytic enzymes.
R. Arnon. In "*Antibodies to Biologically Active Molecules*", B. Cinader, ed., Pergamon Press, Oxford, p. 153 (1966).
2. Homology and Phylogeny of Proteolytic enzymes. In: "*Symposium On Structure-Function Relationship of Proteolytic Enzymes* Copenhagen, Munksgaard, H. Neurath, R. Bradshaw and R. Arnon. p. 113 (1970).
3. Papain
R. Arnon. In "*Methods in Enzymology*", G.E. Perlmann and L. Lorand, eds. **19**, p. 226 Academic Press (1970).
4. Antibodies to Enzymes - A tool in the study of antigenic specificity determinants. R. Arnon. "*Current Topics in Microbiology and Immunology*", Vol. 54, 47 (1971).
5. Immunochemistry of Enzymes.
R. Arnon. In "*The Antigens*", Vol. **I**, p. 87, M. Sela, (ed) Academic Press, N.Y. (1973).
6. Immunological Approaches to Control of Multiple Sclerosis. Desensitization Studies.. Arnon,. *Scientific Conference on Multiple Sclerosis*. London. p. 271 (1975).
7. Immunochemistry of Lysozyme.
R. Arnon. In "*Immunochemistry of Enzymes and their Antibodies*", R.J. Salton, ed., John Wiley and Sons, N.Y., p. **1** (1976).
8. Site-directed tumor chemotherapy.
R. Arnon. McGraw-Hill Encyclopedia for Science and Technology, Year Book. (1976).
9. Novel application for antibodies.
R. Arnon. In "*Biotechnological Applications of Proteins and Enzymes*", Z. Bohack and N. Sharon, eds., p. 247, Academic Press. (1977).
10. Molecular basis of immunogenicity and antigenicity.
R. Arnon and B. Geiger. In "*Immunochemistry*", L.E. Glynn, and M.W. Steward, eds., John Wiley and Sons, p. 307 (1978).
11. Hexosaminidases A and B from human placenta.
B. Geiger and R. Arnon. In "*Methods in Enzymology*", V. Ginsburg, ed., Vol. **L**, p. 547, (Chapter 59) (1978).
12. The chemistry of antigenic determinants on protein molecules.
R. Arnon. In "*Influenza Virus Hemagglutinin*", W.G. Laver and R. Weid, eds., Springer Verlag, Vienna, N.Y., p. 225-241 (1977).
13. Experimental allergic encephalomyelitis.

- M. Sela, D. Teitelbaum and R. Arnon. In "*The Menarini Series on Immunopathology*", Vol. 1. First Symposium on Organ Specific Autoimmunity. Cremona, Italy (June 1977) P.A. Miescher, ed., Schwabe Co. Basel, p. 9-21 (1978).
14. The chemistry of antigenic determinants on protein molecules.
R. Arnon. In "*Immunity in Parasitic Diseases*", A. Capron and P. ery, eds. (Grigon) *INSERM*, 72, p. 11 (1977).
 15. Site-directed tumor chemotherapy.
R. Arnon, *Comprehensive Therapy* 4, 68-73 (1978).
 16. Anti-tumor antibodies as carriers for anti-cancer drugs.
R. Arnon. In "*Tumor-Associated Antigens and their Specific Immune Response*", Proc. of Sero Symposium, F. Spreafico and R. Arnon, eds., Academic Press Vol. 16, p. 287-304 (1979).
 17. Anti-viral activity induced by synthetic peptides corresponding to regions in viral neutralization.
R. Arnon. *Pharmacology and Therapeutics*. 6, 275-289 (1979).
 18. Antibodies as carriers for oncostatic-materials.
R. Arnon, E. Hurwitz and M. Sela. *Recent Results in Cancer Res.* 75, 236-245 (1980).
 19. Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogs.
R. Arnon and D. Teitelbaum. In "*The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis*", A.N. Davison and M.L. Cuzner, eds., Academic Press, p. 105-107 (1980).
 20. Immunochemical research in the fight against diseases.
R. Arnon. In "*Robert Koch Beitrage und Mitteilungen*". Vol. 2, p. 13-35 (1980).
 21. Chemically-defined anti-viral vaccines.
R. Arnon, *Ann. Rev. Microbiol.* 34, 593-618 (1980).
 22. Anti-viral antibodies obtained with aqueous solution of a synthetic antigen.
M. Sela and R. Arnon. In "*New Developments with Human and Veterinary Vaccines*". A. Mizrahi, I. Hertman, M.A. Klinberg and A. Kohn, eds, AlanR. Liss, Inc., N.Y. p. 315-323 (1980).
 23. Experimental allergic encephalomyelitis - Susceptibility and suppression.
Ruth Arnon. *Immunol. Rev.* 55, 5-30 (1981).
 24. Immunological approaches to the vaccines of the future.
M. Sela and R. Arnon. In "*Biological Products for Viral Diseases*", P.A. Bachmann, ed., London, Taylor and Francis, 21-37 (1981).

25. Development of synthetic anti-viral vaccines.
R. Arnon. In "*Trends in Virology*", Behring Institute Mitteilungen. 9. 19-29 (1981).
30. Anti-influenza hemagglutinin response induced with synthetic antigen.
Arnon, M. Shapira and G.M. Muller, in "Genetic Variation among Influenza Viruses", D.P. Nayak, ed., Academic Press, p. 653-662 (1981).
27. Antibodies and dextran as anti-tumor drug carriers.
R. Arnon. In "*Targeting of Drugs*", G. Gregoriadis, J. Senior and A. Trouet, eds., Plenum Press, New York, p. 31-54 (1982).
28. Antibody- and polymer-drug conjugates.
R. Arnon and E. Hurwitz, in "Targeted Drugs", E. Goldberg, ed., New York, Wiley, p. 23-55 (1983).
29. Conformational antigenic determinants in proteins.
R. Arnon, in "*Protein Conformation as an Immunological Signal*", F. Celada, E. Sercarz and V. Schumaker, eds., Plenum Publ. Co., p. 157-164 (1983).
30. Les antigenes et vaccins synthétiques.
R. Arnon and M. Sela. *La Recherche* **14**. 345-358 (1983).
31. Anti-influenza response induced with synthetic antigen.
R. Arnon, M. Jibson, G. Muller and M. Shapira. *Adv. Immunopharmacology*. 2, J.W. Hadden, ed., Pergamon Press, Oxford, p. 421-427 (1983).
32. Synthetic vaccines.
R. Arnon, M. Shapira and C.O. Jacob, J. *Immunol. Methods* **61**, 261-273 (1983).
33. Synthetic vaccines.
R. Arnon, C.O. Jacob and M. Shapira, in "*Progress in Immunology*". V, Y. Yamamura and T. Tada, eds, Academic Press. P. 1327-1341 (1983).
34. Antigenic determinants of proteins and synthetic vaccines.
R. Arnon, in "Contribution of Chemical Biology to the Biomedical Sciences", A. Dean, R. Goldberg and A. Schechter, eds, Academic Press. p. 187-198 (1984).
35. Identification of antigenic determinants and their application in synthetic vaccines.
R. Arnon. In "*New Approaches to Vaccine Development*". R. Bell and G. Torrigiani, eds. Basel, Schwabe: 44-65 (1984).
36. Synthetic vaccine R. Arnon. In: "*Immune intervention*". Vol 1. New trends in Vaccines. Ivan Roitt Ed. Academic Press. P. 93-116 (1984).
37. Anti-influenza synthetic vaccine.
R. Arnon and M. Shapira. In "*Modern Approaches to Vaccines*," R. M. Chanock and R. A. Lerner Eds, Cold Spring Harbor Laboratory Press p. 109-114 (1984).
38. Synthetic antigens and vaccines.
M. Sela and R. Arnon. "*Interdisciplinary Sci. Rev*". 9. 271 (1984).

39. Synthetic approaches to vaccination against cholera toxin.
M. Sela, C.O. Jacob and R. Arnon. "Modern Approaches to Vaccines,"
R.M. Chanock and R.A. Lerner, Eds. Cold Spring Harbor Laboratory Press. 87-92 (1984).
40. Synthetic peptides Vaccines.
R. Arnon. In: "Immunochemistry of Viruses. The Basis for Serodiagnosis" M.H.V. Van Regenmortel and A.R. Neurath, Eds. Amsterdam, Elsevier. P. 139-152 (1985).
41. Synthetic Vaccines: Present and Future.
R. Arnon and M. Sela. Ann. Inst. Pasteur/Immunol. **136 D**, 271-282 (1985).
42. Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy
R. Arnon, B. Schechter and W. Wilchek. In "UCLA Symposium on Monoclonal Antibodies and Cancer Therapy". Monoclonal Antibodies and Cancer Therapy, pps. 243-256 Alan R. Liss, Inc. (1985).
43. Monoclonal antibodies as carriers for immunotargeting of drugs.
R. Arnon and E. Hurwitz. In "Monoclonal Antibodies for Cancer Detection and Therapy" R.W. Baldwin, ed. Academic Press. p 365-383 (1985).
44. Synthetic peptides as the basis for future vaccines. Application in the influenza and cholera toxin systems.
R. Arnon. 3rd. International Congress of Immunopharmacology. Florence. May 6-9, (1985)
45. Anti-influenza immune response induced by synthetic peptides.
M. Shapira and R. Arnon in UCLA Symposium on "Options for the control of Influenza." Pages 391-406 Published by Alan R. Liss, Inc. (1986).
46. Synthetic peptides with antigenic specificity for bacterial toxins.
M. Sela, R. Arnon and C.O. Jacob. In: "Ciba Symposium 119".
Published by John Wiley & Sons, p. 184-195 (1986).
47. Immunity to heat-labile enterotoxins of porcine and human Escherichia coli strains achieved with synthetic cholera toxins.
C.O. Jacob, R. Arnon and R. A. Finkelstein. *Infect. & Immunity*. p. 562-567 May, (1986).
48. Synthetic Peptides as the basis for future vaccines.
Ruth Arnon. *TIBS*. Vol. **11**, pp. 521-526 (1986).
49. Synthetic Peptides as the basis for future vaccines. Application in the influenza and cholera toxin systems.
Ruth Arnon. In "Advances in Immunopharmacology" Vol 3, L. Chedid, J.W. Hadden, F. Spreafico, P. Dukor and D. Pilloughby (eds), Pergamon Press. (1986).
50. Peptides as Immunogens: Prospects for Synthetic Vaccines.
R. Arnon. "Current topics in Microbiology and Immunology". Vol. 130. Springer-Verlag, Berlin-Heidelberg. p. 1-12 (1986).
51. Synthetic peptides as a basis for anti-influenza and anti-cholera vaccines.
Ruth Arnon, Michal Shapira and Chaim O. Jacob. In: *Contributions to Vaccines: New Concepts and Developments*. Ed. by P.T. Loverde, pp. 333-341 (1988).

52. Suppression of Demyelinating Diseases by Synthetic Copolymers.
R. Arnon and D. Teitelbaum, In: "*A multidisciplinary approach to myelin disease*". (Ed. by G. Serlupi Crescenzi). Plenum Publishing Co., pp. 243-250 (1988).
53. Synthetic Antigens and Vaccines.
Ruth Arnon, NATO, ASI. Cape Sounion. Greece. 1988.
54. Immunological Studies on One Defined Protein Region The "*Loop*" of *Lysozyme*".
R. Arnon, M. Sela and I. Pecht. In: "*The Immune Response to Structurally Defined Proteins: The Lysozyme Model*". (Eds. S. Smith-Gill and E. Sercarz). Adenine Press. 315-323 (1989).
55. The use of antibodies and polymers as carriers of cytotoxic drugs in
The treatment of cancer.
R. Arnon, E. Hurwitz and B. Schechter. In: "*Drug Carrier Systems*".
(Eds) F.H.D. Roerdink and A.M. Kroon. John Wiley and Sons, Ltd. **33 - 56** (1989).
56. Synthetic peptide toxoid vaccines against Shiga Dysentery.
R. Arnon., I. Harari., and G. Keusch. Synthetic peptide toxoid vaccines against Shiga
dysentery. In: "*New Generation Vaccines*". Eds. G.C. Woodrow and M.M. Levine.
Marcel Dekker, N.Y. pp. **688-697** (1990)

57. Clinical trials of Cop 1 in Multiple Sclerosis.
M.B. Bornstein, S. Slagle, M.S.W. Weitzman, M. Crystal, A.E. Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, A.E. Miller, E. Dexler, K. Marshall, S.M. Appel, L. Rolak, R. Arnon, M. Sela, I. Jacobsohn and D. Teitelbaum.
In: "*Handbook of Multiple Sclerosis*". Ed. S.B. Cook. Marcel Dekker Inc. N.Y.
p. 469-480 (1990).
58. Complement and *Schistosoma mansoni*.
Z. Fishelson, M. Parizade, Y. Ghendler and R. Arnon. In: "*Complement and Inflammation*" 3rd. European Meeting on Complement in human disease.
Z.Starsia and U.Nydegger, (eds). 7, 123 (1990).
59. Immuno-parasitological parameters in schistosomiasis - a perspective view of a vaccine-oriented immunochemist.
Ruth Arnon. *vaccine*. Vol. 9, pp. 379-394 (1991).
60. Biological applications of synthetic polypeptides.
R. Arnon. In: "*Biotechnology: Bridging Research and Applications*".
Proceedings of the U.S.-Israel Research Conference on Advances in Applied Biotechnology. (eds) D. Kamely, A.M. Chakrabarty and S.E. Kornguth.
Kluwer Academic Publishers, pp. 1-12 (1991).
61. Complexes and conjugates of Cis-Pt for Immunotargeted chemotherapy.
R.Arnon, B. Schechter and M. Wilchek. In: "*Immunobiology of Proteins and Peptides*"
VI. Z. Atassi (Ed) Advances in Experimental Medicine and Biology. Vol 303,
pp. 79-90 (1991)
62. Synthetic peptides as the basis for vaccines against influenza virus and bacterial toxins.
Ruth Arnon. *J. Controlled Release*. 19, pp. 7-14 (1992).
63. Structural basis of antigenic specificity and design of new vaccines.
R. Arnon and M.H. Van Regenmortel. *FASEB J*. 6, 3265-3274 (1992).
64. Synthetic Peptides as Vaccines.
Ruth Arnon and Robert J. Horwitz. *Current Opinion in Immunology*, 4, 449-453 (1992).
65. Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases.
M. Sela and R. Arnon. *Vaccine*. 10, 14, 991-999 (1992).
66. Immunomodulation of experimental allergic encephalomyelitis.
R. Arnon and D. Teitelbaum. *Isr. J. Med. Sci.* 29, 175-181 (1993).
67. Development of Synthetic Vaccines.
R. Arnon In: "*8th International Congress Immunology, Budapest*". (1993).
68. Synthetic peptide based vaccines against bacterial toxins and influenza.
R. Arnon. In: *Recombinant and Synthetic Vaccines*. Edited by Talwar., G.P. et. al., Narosa Publishing House, New Delhi, India. 388-394 (1994).
69. Influenza.

- R.J. Horwitz and R. Arnon. In: "*Synthetic Vaccines*". (ed) Bruce H. Nicholson. Published by Blackwell Scientific Publications. **471-493** (1994).
70. Peptide Vaccines.
R. Arnon, M. Sela. In: "*Immunological Recognition of Peptides in Medicine and Biology*". (eds) Zegers, Boersma, Claassen. **245-254** (1995).
 71. Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection.
R. Arnon and R. Levi. In: "*Advances in Experimental Medicine and Biology*" *Novel Strategies in the Design and Production of Vaccines*. (eds) S. Cohen and A. Shafferman. Published by Plenum Press . **23-29** (1996).
 72. The development of Cop 1 (Copaxone®), an innovative drug for the treatment of Multiple Sclerosis - personal reflections.
R. Arnon. *Immunology Letts.* **50, 1-15** (1996).
 73. Copolymer 1: from basic research to clinical application.
D. Teitelbaum, R. Arnon and M. Sela. *Cellular and Molecular Life Sciences.* **53, 24-28** (1997).
 74. Cop 1 as a candidate drug for multiple sclerosis.
D. Teitelbaum, R. Arnon and M. Sela. *Proc. 3rd IWCN Meeting on: Disease models and Mechanisms. J. Neural. Transm. Vol 3-4: (Suppl)* **49, 85-91** (1997).
 75. Copolymer 1 from the Laboratory to FDA.
D. Teitelbaum, M. Sela and R. Arnon. *Israel J. of Medical Sci.* **33, 280-284, (1977)**.
 76. Design of peptides and polypeptides vaccines.
T. Ben Yedidia and R. Arnon. *Current Opin. in Biotech.* **8, 442-448** (1997).
 77. Tissue selective affinity targeting using the avidin-biotin system.
Limor Chen, Bilha Schechter, Ruth Arnon and Meir Wilchek.
Research Overview. *Drug Development Research.* **50: 258-271** (2000).
 78. A novel approach to vaccine design - Epitope-based vaccines.
Ruth Arnon *Biotech International (Bti)* Netherlands. **18, 10-13** (2006)
 79. Neurogenesis and neuroprotection in the CNS - Fundamental elements in therapeutic immunomodulatory treatment of autoimmune neurological disorders.
Rina Aharoni and Ruth Arnon. *Molecular Neurobiology.***36, (3) 245-53** (2007)
 80. Mechanism of action of Glatiramer acetate - mode of action and potential for new applications.
Ruth Arnon and Rina Aharoni. IMAJ (submitted) 2007.
 81. Linkage between immunomodulation, neuroprotection and neurogenesis.
Rina Aharoni and Ruth Arnon *Drug News & Perspectives"* , **22 (6)** 301-313. (2009)
 82. Neuroprotection & Neurogeneration in MS and its Animal Model EAE Effected by Glatiramer Acetate.
Ruth Arnon and Rina Aharoni. *J. Neural Transmission* Vol **116** No 11 1443-1449 (2009).